로딩 중…
StockDiggingStockDigging

DAEWOONG CO.,LTD

003090· KOSPI
₩17,570-2.23%
2026-06-19

Price Chart

DAEWOONG CO.,LTD-27.25%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap1.02T KRW
Revenue2.08T KRW
Net Income202.16B KRW
Total Assets3.41T KRW
Net Assets1.85T KRW
Employees349
Value
P/E5.05x
P/B0.55x
PEG0.05x
P/S0.49x
EV/EBITDA90.15x
FCF Yield-3.64%
Profitability
ROE10.91%
ROA5.93%
Op. Margin11.95%
Revenue Growth2.34%
Earnings Growth103.57%
Financial Health
Debt Ratio183.90%
Total Debt1.17T KRW
FCF-37.22B KRW
Cash259.69B KRW
Current Ratio1.20x
Net Debt/EBITDA42.47x
Dividend
Div. Yield1.11%
Div. Growth0.00%
Performance
1Y Return-27.25%
1M Return-10.81%
From 52W High-42.58%
1Y MDD-43.41%
Trading
Volume54,343 shares
Foreign Own.4.98%
Per Share
EPS3,167 KRW
BPS30,030 KRW

Company Info

CEO 윤재춘
Employees 349
Founded 1961
HQ 경기 성남시, KR

Daewoong, established in 1961 as Daehan Vitamin Industry Co., Ltd. and listed in 1973, transitioned to a holding company through a spin-off in 2002. As the holding company of a global healthcare group, it owns 36 subsidiaries including Daewoong Pharmaceutical, engaging in pharmaceutical manufacturing and investment. Daewoong focuses on enhancing global market penetration with Fexuclue, Enavlo, and Nabota, while strengthening K-Bio's status. The company is headquartered in Seongnam, Gyeonggi Province.